A Polyamine Oxidizing Enzyme as a Drug to Treat Breast Cancer

: Breast cancer is the most common type of malignancy among ladies (around 30% of newly diagnosed patients every year). To date, various modern treatment modalities for breast cancer, such as radiotherapy, surgical method, hormonal therapy, and chemotherapeutic drug utilisation, are available. However, adverse drug reactions, therapeutic resistance, metastasis, or cancer reoccurrence chances remain the primary causes of mortality for breast cancer patients. To overcome all the potential drawbacks, we need to investigate novel techniques and strategies previously not considered and treat breast cancer effectively with safety and efficacy. For centuries, we utilise phytochemicals to treat various diseases because of their safety, low-cost & least or no side effects. Recently, naturally produced phytochemicals gain immense attention as potential breast cancer therapeutics because of their ideal characteristics; for instance, they operate via modulating molecular pathways associated with cancer growth and progression. The primary mechanism involves inhibition of cell proliferation, angiogenesis, migration, invasion, increasing anti-oxidant status, initiation of the arrest of the cell cycle, and apoptosis. Remedial viability gets effectively enhanced when phytochemicals work as adjuvants with chemotherapeutic drugs. This comprehensive review revolves around the latest chemopreventive, chemotherapeutic, and chemoprotective treatments with their molecular mechanisms to treat breast cancer by utilising phytochemicals such as vinca alkaloids, resveratrol, curcumin, paclitaxel, silibinin, quercetin, genistein and epigallocatechin gallate. The authors wish to extend the field of phytochemical study for its scientific validity and its druggability.

Download Full-text

Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies

Biomedicines ◽

10.3390/biomedicines9030290 ◽

2021 ◽

Vol 9 (3) ◽

pp. 290

Author(s):

Smarakan Sneha ◽

Simon C. Baker ◽

Andrew Green ◽

Sarah Storr ◽

Radhika Aiyappa ◽

...

Keyword(s):

Breast Cancer ◽

Cytochrome P450 ◽

Treatment Strategies ◽

Standard Of Care ◽

Therapeutic Index ◽

Cancer Cell Proliferation ◽

Selective Treatment ◽

Standard Of Care Treatment ◽

Future Work ◽

Treat Breast Cancer

Despite significant advances in treatment strategies over the past decade, selective treatment of breast cancer with limited side-effects still remains a great challenge. The cytochrome P450 (CYP) family of enzymes contribute to cancer cell proliferation, cell signaling and drug metabolism with implications for treatment outcomes. A clearer understanding of CYP expression is important in the pathogenesis of breast cancer as several isoforms play critical roles in metabolising steroid hormones and xenobiotics that contribute to the genesis of breast cancer. The purpose of this review is to provide an update on how the presence of CYPs impacts on standard of care (SoC) drugs used to treat breast cancer as well as discuss opportunities to exploit CYP expression for therapeutic intervention. Finally, we provide our thoughts on future work in CYP research with the aim of supporting ongoing efforts to develop drugs with improved therapeutic index for patient benefit.

Download Full-text

Prodrug Delivery Using Dual-Targeting Nanoparticles To Treat Breast Cancer Brain Metastases

Molecular Pharmaceutics ◽

10.1021/acs.molpharmaceut.1c00224 ◽

2021 ◽

Author(s):

Xiufeng Ju ◽

Haiyan Chen ◽

Tongtong Miao ◽

Jiang Ni ◽

Liang Han

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Dual Targeting ◽

Breast Cancer Brain Metastases ◽

Treat Breast Cancer

Download Full-text

New insights on CRISPR/Cas9-based therapy for breast Cancer

Genes and Environment ◽

10.1186/s41021-021-00188-0 ◽

2021 ◽

Vol 43 (1) ◽

Author(s):

Hussein Sabit ◽

Shaimaa Abdel-Ghany ◽

Huseyin Tombuloglu ◽

Emre Cevik ◽

Amany Alqosaibi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Animal Models ◽

Human Cancer ◽

Step Process ◽

Cancer Initiation ◽

Malignant State ◽

Treat Breast Cancer

AbstractCRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.

Download Full-text

Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma

Biomaterials Science ◽

10.1039/c9bm01766f ◽

2020 ◽

Vol 8 (1) ◽

pp. 333-341 ◽

Cited By ~ 7

Author(s):

Roberto Molinaro ◽

Jonathan O. Martinez ◽

Assaf Zinger ◽

Alessandro De Vita ◽

Gianluca Storci ◽

...

Keyword(s):

Breast Cancer ◽

Membrane Proteins ◽

Immune Cells ◽

Inflammatory Pathway ◽

Doxorubicin Delivery ◽

Cancer Lesion ◽

Treat Breast Cancer

Biomimetic nanovesicles deriving from leukocytes membrane proteins, called leukosomes, exhibit increased targeting of cancer vasculature and stroma by exploiting the inflammatory pathway responsible for recruiting immune cells to the cancer lesion.

Download Full-text